Patent Abstract Sessions
Oral patent abstract session: Innovations in Allergy
Sunday, 27 May 2018
Poster patent abstract session: Innovations in Allergy
Monday, 28 May 2018
Patent Abstract Submission is now closed.
Terms: Patent Abstract Submission System
1. Authors can modify the author information, category and core data of their patent abstract directly on the submission system until the deadline given. Please be aware that there will be no extension possible.
2. By submitting this patent abstract, I understand that my patent abstract, including names, is stored electronically and will be published by the Organising Committee on the EAACI website (members' area). Failure to present my patent abstract on-site will result in exclusion from online publishing on the EAACI website.
3. No trade names of products are allowed in oral or poster presentations. Non-proprietary (generic, chemical) names of drugs should be used. Company names can be used in the authors’ affiliation and as a source to materials mentioned in the body of the patent abstract, such as “Imiquimod (3M, Milwaukee, USA) was used to stimulate dendritic cells".
4. Patent abstracts will be reviewed by an expert panel of reviewers. Acceptance of the submitted work is at the discretion of the Scientific Committee.
5. The corresponding author receives all correspondence concerning the patent abstract, and is responsible for informing all co-authors of the status of the patent abstract. The presenting author of a patent abstract must register for the meeting by the given deadline. If EAACI does not receive your registration and payment by the deadline, your patent abstract will be removed from the programme.
6. Consent for publication of individual patient data: For the patent abstracts that contains identifiable information about patients, it is necessary that the patients concerned have given consent for the research to be published. For all patent abstracts that include identifiable patient details (e.g. gender, age, illness, location) or images, written informed consent for the publication of these must be obtained from the patient (or their parent or legal guardian).
7. Filed or published patents should provide the application and/or publication number and priority date.
By agreeing to these terms I confirm that:
a) Written informed consent for publication of these clinical details and/or clinical images included in my patent abstract were obtained from the patient/parent/guardian/relative of the patient. (Please include an explanatory statement in your patent abstract text).
b) The final decision on whether consent to publish is required lies with EAACI.
c) Accepted abstracts will be published on the EAACI Congress 2018 website, on 26 May 2018. In order to have your abstract published on the website you need to be registered for EAACI Congress 2018.
d) EAACI does not take any responsibilities of any confidentiality issues or premature publications of submitted patents.
8. Declaration of Conflict of Interest: Authors should identify whether the patent is licenced and who has taken the license (if the license holder agrees to it).
9. EAACI is committed to ensuring the integrity of its scientific, educational, and research programmes. Patents abstract sessions are meant to create a commercial environment are allergy innovations.
Guidelines: Patent Abstract Submission System
The EAACI Scientific Programme Committee and the Local Organising Committee welcome the submission of original contributions for patent presentation at the congress.
DEADLINE: 22 FEBRUARY 2018 at 23:59 CET - Patent abstracts received after this date will not be considered.
Instructions to Authors
Carefully read the guidelines below before submitting your patent abstract. Acknowledgement of the receipt of your submission will be sent to the corresponding author’s e-mail address immediately upon submission. If you do not receive the confirmation e-mail, please do not submit the patent abstract again, instead please contact the Patent Abstract Team at email@example.com for advice.
You are allowed to be the presenting author of more than one patent abstract.
You are allowed to be a co-author of more than one patent abstract.
Submission of similar patents abstracts from the same group is discouraged.
Please note, a confirmation of consent must be provided in cases where patients, both living or deceased, are visibly identifiable. Should consent not be given, any pictures must be made anonymous by placing sufficient coverage over any identifiable elements; eyes, facial features, characterising marks etc.
Patent Abstract Language and Length
Patent abstracts and presentations must be written in English. The maximum length allowed for a patent abstract is 2500 characters (approximately 350 words) including blank spaces. The patent abstract title, the author(s) or names of institutions are not included in the count of 2500 characters. Tables are allowed - 50 characters per row will be deducted from the word count. Pictures are not allowed.
Presentation Formats and Patent Abstract Topics
Accepted patent abstracts selected by expert reviewers will be presented in any of the following sessions: Oral Patent Abstract Sessions or Thematic Poster Sessions (electronic posters). Authors can indicate their choice of preferred type of presentation in the provided space. In addition, authors should indicate the thematic area (see Patent Abstract Topics) their patent abstract should be assigned to. Please note that the final decisions regarding the allocation and the type of presentation of the submitted patent abstract will be made by the Scientific Programme Committee.
It is the author’s responsibility to submit a correct patent abstract. Any errors in spelling, grammar or scientific fact will be reproduced as typed by the author as no editing will be done by EAACI. Please note that each year a number of patent abstracts are rejected because of poor English or because they contain no/incomplete data.
Notification of Acceptance
Notifications of acceptance or rejection of the abstracts will be sent to the corresponding author of the abstract by March 2018.
The corresponding author receives all correspondence concerning the patent abstract, and is responsible for informing all co-authors of the status of the patent abstract.
With the notification of acceptance, patent abstract presenters will be informed about the time and date of their presentation, and are asked to reconfirm their attendance. EAACI cannot guarantee that presenting authors who do not show up to present their patent abstract during the session will be accepted for patent abstract presentations at future congresses.
Registration and Publication of Patent Abstracts
The presenting author of a patent abstract must register for the congress. Until 15 March 2018 the presenting author is offered a special extended “early fee”. The registration fee may be refunded if the patent abstract is rejected. Please note that some countries require a visa to visit Germany.
Assistance and Contact Information
For any assistance for the submission of the patent abstract please contact the Patent Abstract Team at: firstname.lastname@example.org